Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while mitigating off-target effects in normal tissues, the concept of prodrug-based bispecific antibodies has...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523693/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591699605454848 |
|---|---|
| author | Zhijuan Ai Zhijuan Ai Bing Wang Yunlong Song Panpan Cheng Xinlin Liu Xinlin Liu Peng Sun |
| author_facet | Zhijuan Ai Zhijuan Ai Bing Wang Yunlong Song Panpan Cheng Xinlin Liu Xinlin Liu Peng Sun |
| author_sort | Zhijuan Ai |
| collection | DOAJ |
| description | Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while mitigating off-target effects in normal tissues, the concept of prodrug-based bispecific antibodies has emerged. This review delineates the various mechanisms underlying the action of prodrug-based bispecific antibodies, including protease-mediated activation, steric hindrance release via proteolytic processing, activation by soluble factors, conditional assembly, and chain exchange-mediated activation. We also address the critical challenges that must be overcome to optimize the development and clinical application of these sophisticated therapeutic agents. |
| format | Article |
| id | doaj-art-59a96116744d4fa6a3079a967e66f8ff |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-59a96116744d4fa6a3079a967e66f8ff2025-01-22T07:11:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011610.3389/fimmu.2025.15236931523693Prodrug-based bispecific antibodies for cancer therapy: advances and future directionsZhijuan Ai0Zhijuan Ai1Bing Wang2Yunlong Song3Panpan Cheng4Xinlin Liu5Xinlin Liu6Peng Sun7The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaQingdao Cancer Institute, Qingdao, ChinaBiomedical Center of Qingdao University, Qingdao University, Qingdao, ChinaQingdao Municipal Center for Disease Control and Prevention, Qingdao Institute of Preventive Medicine, Qingdao, ChinaQingdao Municipal Center for Disease Control and Prevention, Qingdao Institute of Preventive Medicine, Qingdao, ChinaThe Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, ChinaQingdao Cancer Institute, Qingdao, ChinaDepartment of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, ChinaBispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while mitigating off-target effects in normal tissues, the concept of prodrug-based bispecific antibodies has emerged. This review delineates the various mechanisms underlying the action of prodrug-based bispecific antibodies, including protease-mediated activation, steric hindrance release via proteolytic processing, activation by soluble factors, conditional assembly, and chain exchange-mediated activation. We also address the critical challenges that must be overcome to optimize the development and clinical application of these sophisticated therapeutic agents.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523693/fullbispecific antibodiesprodrugcancer therapymechanismtherapeutic efficacy |
| spellingShingle | Zhijuan Ai Zhijuan Ai Bing Wang Yunlong Song Panpan Cheng Xinlin Liu Xinlin Liu Peng Sun Prodrug-based bispecific antibodies for cancer therapy: advances and future directions Frontiers in Immunology bispecific antibodies prodrug cancer therapy mechanism therapeutic efficacy |
| title | Prodrug-based bispecific antibodies for cancer therapy: advances and future directions |
| title_full | Prodrug-based bispecific antibodies for cancer therapy: advances and future directions |
| title_fullStr | Prodrug-based bispecific antibodies for cancer therapy: advances and future directions |
| title_full_unstemmed | Prodrug-based bispecific antibodies for cancer therapy: advances and future directions |
| title_short | Prodrug-based bispecific antibodies for cancer therapy: advances and future directions |
| title_sort | prodrug based bispecific antibodies for cancer therapy advances and future directions |
| topic | bispecific antibodies prodrug cancer therapy mechanism therapeutic efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1523693/full |
| work_keys_str_mv | AT zhijuanai prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT zhijuanai prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT bingwang prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT yunlongsong prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT panpancheng prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT xinlinliu prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT xinlinliu prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections AT pengsun prodrugbasedbispecificantibodiesforcancertherapyadvancesandfuturedirections |